Seoul, South Korea

Jong-Eun Oh


Average Co-Inventor Count = 9.6

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1999-2000

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Jong-Eun Oh in Immunosuppressive Agents

Introduction

Jong-Eun Oh is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of immunology through his innovative research and patents. With a total of 2 patents, his work focuses on the application of natural compounds in medical treatments.

Latest Patents

One of Jong-Eun Oh's latest patents is centered on the use of rosmarinic acid and its derivatives as immunosuppressive agents. This invention highlights the ability of rosmarinic acid to inhibit the binding of ligand peptides to the Lck SH2 domain, which is crucial in T cell signal transduction. The findings suggest that these compounds can effectively suppress immune responses, making them applicable for treating conditions such as graft rejection, graft-versus-host disease (GVHD), autoimmune diseases, and inflammatory diseases.

Another patent involves the development of antibiotic peptides, which further showcases his commitment to advancing medical science through innovative solutions.

Career Highlights

Jong-Eun Oh is affiliated with the Mogam Biotechnology Research Institute, where he conducts his research. His work has garnered attention for its potential impact on therapeutic strategies in immunology.

Collaborations

He collaborates with esteemed colleagues, including Keun-Hyeung Lee and Sung-Yu Hong, who contribute to his research endeavors and enhance the scope of his innovations.

Conclusion

Jong-Eun Oh's contributions to the field of immunology through his patents reflect his dedication to advancing medical science. His innovative use of natural compounds like rosmarinic acid holds promise for future treatments in various medical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…